Genetic Ablation of the Amplified-in-Breast Cancer 1 Inhibits Spontaneous Prostate Cancer Progression in Mice
- 15 June 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (12) , 5965-5975
- https://doi.org/10.1158/0008-5472.can-06-3168
Abstract
Although the amplified-in-breast cancer 1 (AIB1; SRC-3, ACTR, or NCoA3) was defined as a coactivator for androgen receptor (AR) by in vitro studies, its role in AR-mediated prostate development and prostate cancer remained unexplored. We report here that AIB1 is expressed in the basal and stromal cells but not in the epithelial cells of the normal mouse prostates. AIB1 deficiency only slightly delayed prostate growth and had no effect on androgen-dependent prostate regeneration, suggesting an unessential role of AIB1 in AR function in the prostate. Surprisingly, when prostate tumorigenesis was induced by the SV40 transgene in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, AIB1 expression was observed in certain epithelial cells of the prostate intraepithelial neoplasia (PIN) and well-differentiated carcinoma and in almost all cells of the poorly differentiated carcinoma. After AIB1 was genetically inactivated in AIB1−/−/TRAMP mice, the progression of prostate tumorigenesis in most AIB1−/−/TRAMP mice was arrested at the well-differentiated carcinoma stage. Wild-type (WT)/TRAMP mice developed progressive, multifocal, and metastatic prostate tumors and died between 25 and 34 weeks. In contrast, AIB1−/−/TRAMP mice only exhibited PIN and early-stage well-differentiated carcinoma by 39 weeks. AIB1−/−/TRAMP prostates showed much lower cell proliferation than WT/TRAMP prostates. Most AIB1−/−/TRAMP mice could survive more than 35 weeks and died with other types of tumors or unknown reasons. Our results indicate that induction of AIB1 expression in partially transformed epithelial cells is essential for progression of prostate tumorigenesis into poorly differentiated carcinoma. Inhibition of AIB1 expression or function in the prostate epithelium may be a potential strategy to suppress prostate cancer initiation and progression. [Cancer Res 2007;67(12):5965–75]Keywords
All Related Versions
This publication has 51 references indexed in Scilit:
- Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary glandProceedings of the National Academy of Sciences, 2006
- Direct Control of Cell Cycle Gene Expression by Proto-Oncogene Product ACTR, and Its Autoregulation Underlies Its Transforming ActivityMolecular and Cellular Biology, 2006
- Caveolin-1 Promotes Tumor Progression in an Autochthonous Mouse Model of Prostate Cancer: Genetic Ablation of Cav-1 Delays Advanced Prostate Tumor Development in Tramp MiceJournal of Urology, 2006
- Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate ModelClinical Cancer Research, 2004
- The Transcriptional Co-activator p/CIP (NCoA-3) Is Up-regulated by STAT6 and Serves as a Positive Regulator of Transcriptional Activation by STAT6Published by Elsevier ,2004
- Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancerThe Prostate, 2004
- Role of the Steroid Receptor Coactivator SRC-3 in Cell GrowthMolecular and Cellular Biology, 2003
- Gene Amplification and Expression of the Steroid Receptor Coactivator SRC3 (AIB1) in Sporadic Breast and Endometrial CarcinomasHormone and Metabolic Research, 2001
- RAC‐3 is a NF‐κB coactivatorFEBS Letters, 2000
- AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian CancerScience, 1997